Biothera Pharmaceuticals, Inc.

Biothera Pharmaceuticals, Inc. is a US-based privately held, clinical stage immuno-oncology company that focuses on developing Imprime PGG, their proprietary immunotherapy, in combination with immune checkpoint inhibitors (CPIs) for various cancer indications. Imprime PGG is a biologic innate immune modulator known for activating the immune system and coordinating anti-cancer immune responses, resulting in increased activation of cancer-specific T cells. The company has established clinical research agreements with Merck, Genentech, and AstraZeneca to assess Imprime PGG in combination with CPIs for multiple cancer indications, including metastatic triple negative breast cancer, head and neck cancer, and colorectal cancer. Promisingly, Imprime PGG has demonstrated strong evidence of tolerability in clinical trials involving more than 500 subjects, including over 400 cancer patients. Founded in 1997, Biothera Pharmaceuticals operates within the Biotechnology and Medical Devices industries. For more information, visit their website at www.biothera.com.